Cochrane · systematic review · CD000366
Inositol in preterm infants at risk for or having respiratory distress syndrome
Howlett, A, Ohlsson, A, Plakkal, N · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
NeonatalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 7.7%Moderate 9 · 69.2%High 3 · 23.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) compared to control for preterm infants at risk for or having respiratory distress syndrome (Comparison 1)
Population: preterm infants at risk for or having respiratory distress syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infant death (age < 1 year) Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 0.89 [0.71, 1.13] | 5 studies · 1115 participants | Low |
Bronchopulmonary dysplasia (at 36 to 38 weeks' PMA) Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 1.04 [0.9, 1.2] | 2 studies · 737 participants | Moderate |
ROP, stage ≥ 3 or ≥ 2 Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 0.89 [0.75, 1.06] | 3 studies · 810 participants | Moderate |
Sepsis (early or late onset) Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 1.21 [0.95, 1.54] | 4 studies · 1067 participants | Moderate |
Necrotizing enterocolitis (suspected or proven) Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 0.94 [0.64, 1.39] | 5 studies · 1115 participants | Moderate |
Intraventricular haemorrhage, grade > 2 Inositol supplementation to preterm infants (repeat doses in any amount and any duration of treatment) vs control | RR 0.77 [0.58, 1.01] | 5 studies · 1103 participants | Moderate |
Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA compared to placebo for preterm infants at risk for or having respiratory distress syndrome (Comparison 3)
Population: preterm infants at risk for or having respiratory distress syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Type 1 ROP or death before determination of ROP outcome using the adjudicated ROP outcome Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 1.28 [0.99, 1.67] | 2 studies · 679 participants | Moderate |
Type 1 ROP including adjudicated ROP outcome Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 1.24 [0.82, 1.86] | 2 studies · 605 participants | Moderate |
All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 1.35 [0.91, 2] | 2 studies · 701 participants | Moderate |
BPD or death by it prior to 37 weeks' PMA (outcomes collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 1.01 [0.87, 1.16] | 2 studies · 616 participants | High |
Severe IVH (grade 3 or 4) Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 0.92 [0.65, 1.29] | 2 studies · 690 participants | Moderate |
Late‐onset sepsis (> 72 hours of age) Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 1.33 [1, 1.75] | 2 studies · 701 participants | High |
Suspected or proven NEC Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo | RR 0.88 [0.55, 1.41] | 2 studies · 701 participants | High |